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 Abstract  
Being as a relatively new approach of signalling, moving-block scheme significantly increases line 
capacity, especially on congested railways. This paper describes a simulation system for multi-train 
operation under moving-block signalling scheme. The simulator can be used to calculate minimum 
headways and safety characteristics under pre-set timetables or headways and different geographic an 
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Introduction
Japanese encephalitis virus is a mosquito-borne flavivirus that 
causes acute neurological illness. An estimated 35,000–50,000 
cases occur annually in Asia, primarily in children. The case 
fatality rate is high (20–30%) and the incidence of neurological 
or psychiatric sequelae in survivors can approach 50%.1 Given 
the absence of specific therapy for JE, immunization is the only 
disease specific public health intervention available. At least 
In a randomized, double-blind study, 202 healthy adults were randomized to receive a live, attenuated Japanese encepha- 
litis chimeric virus vaccine (Je-cV) and placebo 28 days apart in a cross-over design. a subgroup of 98 volunteers received 
a Je-cV booster at month 6. safety, immunogenicity and persistence of antibodies to month 60 were evaluated.
There were no unexpected adverse events (aes) and the incidence of aes between Je-cV and placebo were similar. 
There were three serious adverse events (sae) and no deaths. a moderately severe case of acute viral illness commenc-
ing 39 days after placebo administration was the only sae considered possibly related to immunization. 99% of vaccine 
recipients achieved a seroprotective antibody titer ≥10 to Je-cV 28 days following the single dose of Je-cV and 97% were 
seroprotected at month 6. Kaplan Meier analysis showed that after a single dose of Je-cV, 87% of the participants who 
were seroprotected at month 6 were still protected at month 60. This rate was 96% among those who received a booster 
immunization at month six. Ninety-five percent of subjects developed a neutralizing titer ≥10 against at least three of the 
four strains of a panel of wild-type Japanese encephalitis virus (JeV) strains on day 28 after immunization. at month 60, 
that proportion was 65% for participants who received a single dose of Je-cV and 75% for the booster group. These re-
sults suggest that Je-cV is safe, well tolerated and that a single dose provides long-lasting immunity to wild-type strains.
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three vaccines are currently licensed. These include a formalin-
inactivated vaccine based on Nakayama strain of JEV grown in 
the brains of suckling mice,2 and the SA14-14-2 strain used as a 
live attenuated vaccine.3 The SA14-14-2 strain grown in the Vero 
cell line is also used as an inactivated vaccine.4 The inactivated, 
mouse brain-derived Biken JE vaccine utilizing the Nakayama 
strain of JEV (JE-VAX®) and the Vero cell-derived, inactivated 
SA14-14-2 vaccine are both licensed outside Asia and are used 
to vaccinate travelers, military personnel and laboratory staff in 
www.landesbioscience.com Human Vaccines 1039
 ReseaRcH papeR ReseaRcH papeR
Figure 1. participant disposition and reason for withdrawal at the end of the treatment phase (day 56) and at month 6, 7, 12, 24, 36, 48 and 60 for partici-
pants treated with a single 3.8 log10 dose of Je-cV and placebo with or without a booster dose of 3.8 log10 Je-cV at month 6. Treatment period withdraw-
als (to day 56): Group a: One treatment-related adverse event (TRae) (mild glomerulonephritis and anemia). Two military deployments/training. all three 
participants received Je-cV but not placebo. Group B: Two instances of protocol non-compliance. One participant with a protocol deviation received 
both Je-cV and placebo while one participant withdrawn for a reason in the “Other” category received only placebo. second dose group withdrawals 
(to month 7): Five withdrawals—lost to follow-up. all participants received vaccine. Long term follow-up withdrawals: (1) One participant was withdrawn 
due to mouse brain-derived, inactivated Je immunization administered between month 48 and month 60. This was required because the participant 
had no detectable JeV antibodies and was required to deploy to a Je endemic area. (2) a total of 125 participants did not attend the annual follow-up 
visit over five years, principally due to military deployments, leaving the service or posting outside the visitation range of the single center study site.
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in almost all cases. Adverse events by study period (day 0 to day 
27 or day 28 to day 56) revealed that regardless of study treat-
ment administered, the highest incidence of AEs was reported 
between day 0 and day 27. Importantly, between day 28 and day 
56, when Group A subjects received placebo and Group B sub-
jects received JE-CV there was no difference in AE incidence. 
Similarly, following the second JE-CV injection, the incidence 
and severity of reactions were lower than after the first injection 
(Table 1).
There were three SAEs during the study and no deaths. Two 
SAEs were unrelated to vaccination (gastroenteritis and post-
hemorroidectomy per-rectum bleeding). A third SAE—acute 
viral illness resulting in hospital admission 8 days after JE-CV 
vaccination—was deemed possibly related to vaccination, due to 
the temporal association. Symptoms included malaise, diarrhea, 
abdominal pain, headache and dizziness.
No JE-CV viremia was detected in post-immunization samples 
at days 14 and 42 and there were no clinically relevant changes 
in mean hematology values compared to screening. Abnormal 
liver function test results were presented by four subjects 14 
days following injection of either placebo (n = 2) or JE-CV (n 
= 2). All four cases were considered possibly related to vaccina-
tion, resolved spontaneously and none were associated with a 
clinical syndrome. The mean values of the biochemistry param-
eters were within normal range in the subjects who received the 
booster. Seven participants reported elevated body temperature 
non-JEV endemic countries. Routine immunization with Biken 
JE vaccine is no longer undertaken in Japan and production was 
discontinued in December 2005.5 Japanese encephalitis chimeric 
virus vaccine (JE-CV) is a live, attenuated vaccine grown in Vero 
cells. The vaccine virus was constructed by removing pre-mem-
brane and envelope coding sequences from the yellow fever (YF) 
vaccine virus (strain 17D) and replacing them with the corre-
sponding sequences from the attenuated JEV strain, SA14-14-2.6 
The objectives of this study were to assess: (1) the safety profile 
of the vaccine; (2) participant seroconversion to JE-CV follow-
ing primary immunization; (3) the effect of a booster immuni-
zation given at 6 months; (4) the persistence of the neutralizing 
responses to JE-CV up to 60 months (5 years) after a single dose 
of JE-CV followed or not by a booster 6 months later; and (5) 
the neutralization of a panel of four wild-type JEV isolates from 
different genotypes.
Results
Study population. 202 participants were enrolled and random-
ized into the two cross-over Groups A and B, 198 of whom (99 
per group) attended the end of treatment period visit at day 56. At 
the month 6 follow-up visit, 55 and 43 participants from Groups 
A and B respectively were revaccinated with JE-CV (Group D, n 
= 98) and followed to year 5 while 103 participants from Groups 
A and B were included in Group C to be followed to year 5, with-
out receiving any vaccination at month 6 (Fig. 1).
Most participants were male (86%) and Caucasian (95%) 
with a mean age of 27 years (range 18–55 years) and a mean 
weight of 80 kg (range 53–121 kg). There were no significant 
differences (p > 0.144, analysis of variance [ANOVA]) between 
the baseline demographic characteristics (gender, ethnicity, 
age, weight, height, body mass index and baseline flavivirus 
status) of the treatment groups. The study was conducted in a 
military population and a disproportionally higher number of 
males were enrolled (reflective of the overall military demogra-
phy). The effect of sex on immunological and safety endpoints 
was not assessed as part of this study. Ten percent (6 and 15 
participants from Groups A and B respectively) of the study 
population showed evidence (neutralizing titer of PRNT
50
 ≥10) 
of prior exposure to JE, YF or other flaviviruses, before JE-CV 
administration. Evidence of prior exposure to JE-serocomplex 
viruses or dengue virus specifically was seen in 3 and 7 partici-
pants in Groups A and B, respectively. Measurement of anti-
body responses to homologous JE-CV in the Intent to Treat 
(ITT) population with prior flavivirus exposure is presented 
separately in the results.
Reactogenicity and safety. The incidence of treatment related 
adverse events (TRAEs) deemed possibly, probably or definitely 
related to immunization with either JE-CV or placebo occurring 
in more than one participant was 23% in both groups (Table 
1). Adverse reactions were either mild (n = 79) or moderate (n = 
13) during the cross-over treatment period; there were no severe 
TRAEs. The most commonly reported reactions reported within 
28 days after immunization with JE-CV were headache, injec-
tion site pain and injection site reactions, which lasted 1–3 days 
Table 1. Treatment related adverse events occurring in ≥1% of healthy 
participants following treatment with a single dose of Je-cV or placebo 
at Month 0, and following a booster dose of Je-cV at month 6 (safety 
population)
Treatment Related 
Adverse events
n (%)
JE-CV 
n = 201 
n (%)
Placebo 
n = 199 
n (%)
JE-CV 
booster 
n = 98 
n (%)
Total 68 71 4
participants with treatment 
related adverse events
47 (23) 45 (23) 4 (4.0)
Headache 12 (6.0) 10 (5.0) 0
Injection site pain 7 (3.5) 5 (2.5) 0
Injection site reaction 6 (3.0) 4 (2.0) 0
Lethargy 5 (2.5) 2 (1.0) 0
Viral infection 5 (2.5) 10 (5.0) 0
Injection site erythema 4 (2.0) 5 (2.5) 0
Fatigue 3 (1.5) 2 (1.0) 0
Lymphadenopathy 2 (1.0) 0 0
Injection site swelling 2 (1.0) 6 (3.0) 1 (1.0)
Diarrhea 2 (1.0) 1 (0.5) 0
Nausea 2 (1.0) 2 (1.0) 0
pyrexia 2 (1.0) 2 (1.0) 3 (3.0)
LFT abnormal 2 (1.0) 2 (1.0) 0
Myalgia 2 (1.0) 2 (1.0) 0
URTI 2 (1.0) 9 (4.5) 0
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at six months and then peaked 353 (95% CI 289–432) at month 
seven, after the booster. GMTs were significantly lower (p < 0.05, 
ANOVA) between month 12 and 48 months in the group that 
received a single dose of vaccine compared to the group that 
received a second dose of JE-CV at month 6 (Fig. 3). At month 
36, anti-JE-CV titers were observed to rise in both groups receiv-
ing single or two doses of JE-CV. Seven participants from Group 
C who received a single JE-CV dose and eight subjects from 
Group D who received a booster JE-CV dose demonstrated sero-
conversion (≥four-fold rise) in anti-JE-CV titers between months 
24 to month 60. Two participants of Group C (no booster) who 
were seronegative at month 24 demonstrated seroconversion 
(≥four-fold rise) at month 36. Eight of these subjects received 
non-flavivirus vaccines in preparation for military deployments 
in the 12 months preceding the four-fold rise in titer. Two sub-
jects received treatment for viral illnesses (influenza and uncon-
firmed viral meningitis) and three participants reported travel to 
tropical areas but denied febrile illness during or after travel.
Neutralization of wild-type JEV strains: 99.5% (196/197, 
95% CI 97–100) of participants produced antibodies by day 28 
which neutralized (PRNT
50
 ≥10) at least one strain from a panel 
of four wild-type JEV strains. 95% (187/197, 95% CI 91–98) 
of the participants neutralized at least three of the four strains 
and 85% (168/197, 95% CI 80–90) neutralized them all. The 
responses to each of the wild-type strains tested were lower than 
that against the vaccine virus with neutralization rates vary-
ing from 77 to 97% at day 28 and GMTs from 54% (95% CI 
44–66) to 216 (95% CI 177–263) in previously flavivirus-nega-
tive subjects. Neutralizing antibodies persisted to month 60 with 
65% (30/46, 95% CI 50–79) of the individuals who received 
a single dose of JE-CV still able to neutralize at least three of 
the four strains. In the two-dose group, the corresponding rate 
was 75% (27/36, 95% CI 58–88). In the single dose group, the 
of > 38.1°C for 1–7 days, two after placebo, two after the first 
dose of JE-CV and three after the booster. In addition, one par-
ticipant had an elevated temperature of 38.7°C on admission to 
hospital 39 days after first immunization (this symptom was part 
of the SAE acute viral illness described above).
Immune response to JE-CV: 28 days after immunization 
with JE-CV, 99% of participants seroconverted to JE-CV with 
a PRNT
50
 ≥10 (Table 2). The geometric mean titer (GMT) of 
the neutralizing antibodies from these participants was 317 (95% 
confidence interval [CI] 260–385). At month 6, 97% of partici-
pants had seroprotective antibodies to JE-CV and 100% of par-
ticipants who received a second dose of JE-CV vaccine at month 
six were seroprotected at month seven. The booster elicited a 
≥four-fold titer increase in 27% of recipients, including the three 
subjects who had a neutralizing titer below the protective thresh-
old at month six. The remaining 73% showed either a moderate 
increase or a decrease in JE-CV titer after the booster. At month 
24, seroprotective antibodies were observed in 90% of partici-
pants who received a single dose of JE-CV (Group C) and in 
99% of participants who received two doses of JE-CV (Group D) 
(Table 2).
Long-term immune response to JE-CV (>24 months): Kaplan 
Meier survival analyses performed on the ITT population from 
month 6 provided an estimate of seroprotection at month 60. Of 
participants who received a booster dose, the estimate of seropro-
tection rate at month 60 was 96% (95% CI 89–100) compared 
with 87% (95% CI 78–96) of those who received a single-dose 
of JE-CV. The difference between the distribution of the two 
survival curves became statistically significant only when the 
month 60 time point was included in the analysis (p = 0.046, 
log rank test) (Fig. 2 and Table 3). Geometric mean anti-JE-CV 
neutralizing titers reached a GMT of 317 28 days after immuni-
zation (95% CI 260–385), decreased to 151 (95% CI 125–181) 
Table 2. seroprotection and seroconversion to vaccine (Je-cV) from day 28 to month 60 in healthy participants (ITT population) treated with a single 
dose of Je-cV and placebo followed or not by a booster dose of Je-cV at month 6
Day 28 Month 6 Month 7 Month 12 Month 24 Month 60
Seroconversion after one JE-CV vaccination
pRNT50 ≥20 (primary endpoint)
% 
n/N 
(95% cI)
97% 
191/197 
(94–100)
- - - -
pRNT50 ≥10
% 
n/N 
(95% cI)
99% 
194/197 
(96–100)
- - - -
Seroprotection after one JE-CV vaccination
pRNT50 ≥10
% 
n/N 
(95% cI)
-
97% 
185/191 
(93–99)
-
95% 
72/76 
(87–99)
90% 
64/71 
(81–96)
93% 
43/46 
(82–99)
Seroprotection after booster JE-CV vaccination
pRNT50 ≥10
% 
n/N 
(95% cI)
- -
100% 
97/97 
(96–100)
99% 
79/80 
(93–100)
99% 
69/70 
(92–100)
97% 
35/36 
(85–100)
Seroconversion after booster JE-CV vaccination
pRNT50 ≥10 or ≥4-fold rise in titer)
% 
n/N 
(95% cI)
- -
27% 
26/97 
(18–37)
- - -
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willingness and availability to receive a second dose of JE-CV. 
Better tolerance of JE-CV in Group D participants may have also 
reduced the reported AEs in the booster group compared to pla-
cebo during the treatment period. The safety of JE-CV was con-
firmed in a large-scale phase III safety study that demonstrated a 
similar incidence of drug-related adverse events between JE-CV 
and placebo (submitted).
A neutralizing anti-JEV titer ≥10 is considered seroprotec-
tive,9,10 and this threshold has recently been accepted by regu-
latory authorities as a surrogate marker of protection for the 
licensure of a new inactivated JE vaccine.11 This study has dem-
onstrated that almost all participants develop seroprotective anti-
bodies to JE-CV by day 28. This seroprotective titer is consistent 
with previous studies where 3.8 and 4.0 log
10
 plaque forming unit 
(PFU) doses of JE-CV in non-immune participants resulted in 
91–100% seroconversion with a neutralizing GMT of 128–270 
by day 31.7,8 Japanese encephalitis chimeric virus vaccine has also 
been shown to be effective in non-clinical challenge studies in 
monkeys and mice.6,12 Our study demonstrates that most persons 
living in non-JEV endemic area retain seroprotective titers up to 
at least 60 months after a single dose of JE-CV. In a similar study, 
63% (44/69) of children immunized with a single dose of a live 
attenuated SA14-14-2 vaccine during a study of the effectiveness 
of SA14-14-2 vaccine in Nepal had neutralizing antibody titers 
to SA14-14-2 at 60 months with a GMT of 51.6 (range 11–962). 
However, 20.6% of these children had pre-existing anti-JEV 
antibodies and a sustained boosting effect from subclinical 
JEV infections cannot be ruled out.13 A follow-up study of this 
proportion of subjects with neutral-
izing antibody (PRNT
50
 ≥10) varied 
between 63% (29/46, 95% CI 48–77) 
with a GMT of 20 (95% CI 14–30) 
for the Beijing strain to 78% (36/46, 
95% CI 64–89) for the TVP-8236 
strain (GMT = 44, 95% CI 28–70). 
By comparison, 43/46 (93%) of sub-
jects who received a single immuniza-
tion and who attended the month 60 
visit had neutralizing antibodies to 
JE-CV (PRNT
50
 ≥10) with a GMT 
of 62 (95% CI 43–88). The ratio was 
35/36 (97%) with a GMT of 79 (95% 
CI 54–115) for subjects who received a 
booster. The decline in antibody titers 
to wild-type JEV strains after month 
12 was consistent with the rate of 
decline for neutralizing antibodies to 
the vaccine virus (data not shown).
Flavivirus seroimmune status at 
baseline had no significant effect on 
the neutralizing antibody response to 
JE-CV at day 28 (GMT of 316 [95% 
CI 151–663] in the baseline flavivirus 
seropositive subjects and of 317 [95% 
CI 260–385] in the baseline flavivirus 
naïve populations) and at month six 
[GMT of 243 (95% CI 136–432) and 142 (95% CI 117–173) 
respectively in baseline flavivirus seropositive and naïve popu-
lations; p > 0.05, ANOVA model]. However, one month after 
a booster dose of JE-CV at month six antibody responses were 
significantly higher in the baseline flavivirus seropositive partici-
pants than in the baseline naïve participants, with GMTs against 
JE-CV of 721 (95% CI 338–1538) and 318 (95% CI 260–388), 
respectively (p = 0.0064, ANOVA). 
Discussion
The primary objective of the first phase of the study was to docu-
ment the safety of a single dose of JE-CV vaccine compared with 
a placebo. The reported incidence of reactions after JE-CV vac-
cination was found to be comparable with the incidence after 
placebo injection and, like in two previous JE-CV studies, no 
safety concerns were identified.7,8 There were no unexpected 
AEs or allergic reactions to the vaccine observed during this 
study. Reactions commonly reported in other vaccine trials were 
observed in this study with no difference between the vaccine and 
placebo groups during the treatment period.7,8 It was noted that 
the AE incidence declined as the study progressed, even though 
diary cards were used following each vaccination and this time 
course effect may have reduced the number of treatment-related 
AEs reported at month seven after the second dose of JE-CV. The 
participants administered the second dose of JE-CV (Group D) 
were selected as a convenience sample from participants ran-
domized for initial treatment (Group A and B) based on their 
Figure 2. Kaplan-Meier survival analysis showing seroprotection (pRNT50 > 10) over time for one-dose 
(Group c) and two-dose (Group D) Je-cV groups from month 6 to 60. Kaplan-Meier survival analysis 
was used to determine the proportion of participants maintaining seroconversion to Je-cV from 
month 6 to 60 with separate analyses undertaken for participants given a single dose of vaccine and 
those given two doses of vaccine (log-rank test). participant numbers “at risk,” “failed” and “censored” 
reflect those who attended each visit and a particular study population (i.e. safety or ITT populations) 
(Table 3). Month seven was not performed for the single dose participant with a serology value at 
month seven. pRNT50 values reported at < 10 were converted to a pRNT50 = 5. If a pRNT50 value was 
missing for a visit and the participant returned for the next visit and was seroprotected at that time; 
the participant was assumed to have remained seroprotected at the time of the missing visit. If a 
pRNT50 value was missing for a visit and the participant returned for the next visit and was not sero-
protected (i.e. pRNT50 < 10) at that time, the participant was assumed to have not been seroprotected 
at the time of the missing visit. For participants who missed two consecutive visits, only the data up to 
the missing visits was used for the Kaplan-Meier estimate.
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Table 3. Kaplan-Meier estimate for persistence of neutralizing antibodies (pRNT50 ≥10) to vaccine (Je-cV) from month 6 to 60 in healthy volunteers (ITT 
population) treated with a single dose of Je-cV and placebo followed or not by a booster dose of Je-cV at month 6
Visit
Group C Group D
n
%  
Seroprotected 
(95% CI)
%  
Not seroprotected 
(95% CI)
n
%  
Seroprotected 
(95% CI)
%  
Not seroprotected 
(95% CI)
Month 6
at risk 
Failed 
censored
90 
0 
11
100% 
(100–100)
0% 
(0–0)
95 
0 
0
100% 
(100–100)
0% 
(0–0)
Month 12
at risk 
Failed 
censored
79 
2 
8
98% 
(94–100)
2% 
(0, 6)
85 
1 
8
99% 
(97–100)
1% 
(0–4)
Month 24
at risk 
Failed 
censored
69 
3 
11
93% 
(88–99)
7% 
(1–13)
76 
0 
18
99% 
(97–100)
1% 
(0–4)
Month 36
at risk 
Failed 
censored
55 
1 
6
92% 
(85–98)
8% 
(2–15)
58 
0 
10
99% 
(97–100)
1% 
(0–4)
Month 48
at risk 
Failed 
censored
48 
1 
15
90% 
(82–97)
10% 
(3–18)
48 
0 
16
99% 
(97–100)
1% 
(0–4)
Month 60
at risk 
Failed 
censored
32 
1 
31
87% 
(78–96)
13% 
(4–22)
32 
1 
31
96% 
(89–100)
4% 
(0–11)
Figure 3. GMT and GMT ratio for one-dose (Group c) and two-dose (Group D) from month 6 to 60. The geometric mean ratio was calculated by 
aNOVa and was considered significant if the 95% cI did not contain the value one. significant differences (p < 0.05) in the anti-Je-cV GMT from month 
12 through month 48 are indicated by an asterisks.
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the clinic and 98 participants received a second JE-CV injection 
(convenience sample based on their willingness and availability 
and no formal randomization), with follow-up one month later. 
The study was extended by protocol amendment to allow a long-
term follow-up phase out to 60 months. Participants enrolled in 
the long-term follow-up phase (Group C or Group D for subjects 
followed after one or two doses of JE-CV, respectively) provided 
additional blood samples at 12, 24, 36, 48 and 60 months for 
anti-JEV neutralizing antibody titration. At each yearly visit 
commencing at month 12, participants were questioned about 
their travel, immunizations, any febrile illnesses, hospitalization 
and confirmed flavivirus infections in the 12 months prior to the 
visit using a scripted questionnaire. Particular attention was given 
to flavivirus immunizations. This information, which is stored 
in a military clinical database and the service person’s medical 
file, was checked at the study site. Any participants who received 
a flavivirus vaccine during the long-term follow-up period were 
withdrawn.
Study vaccines. JE-CV is a live attenuated, Japanese enceph-
alitis chimeric virus vaccine grown in Vero cells (previously 
referred to as ChimeriVaxTM-JE). The vaccine used in this study 
was produced at pilot scale as a liquid formulation (Acambis Inc., 
UK, now Sanofi Pasteur, France).8 Vaccine was extemporane-
ously diluted in a sterile solution of vaccine diluent to give a final 
dose of 3.8 log
10
 PFU. The vaccine diluent alone was used as the 
placebo.
The protocol and informed consent forms were approved by 
the Australian Defence Human Research Ethics Committee 
(#292/02). The study was conducted in accord with Good 
Clinical Practice guidelines and local regulatory approvals 
included a clinical trial exemption (#99/2/4014), dealing not 
involving release licence (071/2002) and review by the Gene 
and related Therapies Research Advisory Panel (#2002-02). The 
study is registered under number NCT00981175 (clinicaltrials.
gov) and written informed consent was obtained from each par-
ticipant at the screening visit and prior to the extension phase.
Study subjects. Service personnel aged 18 to 55 years of age 
who were in good general health with no significant medical his-
tory, physical examination findings or clinically significant labo-
ratory results were eligible for the study if they were available for 
the study duration. Service women of child-bearing potential had 
to have a negative serum beta-human chorionic gonadotropin 
result on entry to the study and were required to use hormonal or 
barrier methods of birth control at least one month prior and one 
month following each immunization. Exclusion criteria included 
a history of JE-immunization, known or suspected immuno-
deficiency, prior adverse reactions to a vaccine characterized 
by urticaria or angioedema, transfusion of blood or treatment 
with any blood product within six months of the screening visit, 
administration of another vaccine 30 days preceding screening 
or planned during the treatment period. Service personnel were 
ineligible if they had a clinically significant medical condition, 
abnormal physical examination or abnormal laboratory param-
eter or; body temperature >38.1°C or acute illness within three 
days of inoculation (rescheduling permitted). Service personnel 
also were excluded if they had antibodies to hepatitis C virus, 
Nepalese population demonstrated 96.2% (95% CI 73.1–99.9%) 
protection from this single-dose regimen in these children over a 
60 month period.14 In our study, the immunological benefit of 
the booster dose of JE-CV, given at six months after the first vac-
cination, was real but moderate: a four-fold titer increase after 
boosting was seen in approximately one quarter of the population 
and the GMT increased by a factor of approximately two, back 
to levels seen 28 days after the first immunization. Furthermore 
compared with a single dose, the booster provided only a margin-
ally higher residual seroprotection rate at month 60. The effect 
of a second immunization was even lower in a previous study 
where a second dose of JE-CV was administered 30 days after 
the primary dose. It resulted in three of the 55 participants sero-
converting to JE-CV (log neutralization index >0.7) of which 
one participant’s seroconversion was transient.8 It is explained by 
the neutralization or blunting of viral replication of the injected 
virus by the immune response elicited by the first immunization. 
Despite the observed differences, the long term results of the cur-
rent study support the use of a single dose of JE-CV for primary 
immunization in an adult traveler population.
Our study has demonstrated the capacity for JE-CV to induce 
neutralizing antibodies against a panel of wild-type strains of 
JEV. All licensed JE vaccines are derived from a limited num-
ber of JEV strains and it is generally accepted that they afford 
protection against circulating JEV strains from the four major 
genotypes.15-17
A slight rise in anti-JE-CV titers was observed at month 36. 
This may be due to subclinical flavivirus infections in individuals 
between month seven and month 60.
Prior exposure to flaviviruses had no discernable effect on the 
reactogenicity or safety of JE-CV, and no significant effect on 
the antibody titers one and 6 months after a single vaccination 
with JE-CV. Interestingly, following a booster dose of JE-CV 
at month 6, participants with pre-existing flavivirus antibodies 
had statistically significantly higher anti-JE-CV GMTs at month 
seven compared to participants who were flavivirus naïve at 
baseline. Previous studies demonstrated that JE-CV boosts the 
anti-YFV antibody titer in approximately half of the participants 
immunized previously with YF-VAX® and the titer of neutral-
izing antibodies to JE-CV also were higher in those immunized 
previously with YF-VAX®.7,8
Participants and Methods
The study was a randomized, double-blind, cross-over trial con-
ducted at a single study center in the Australian Defence Force 
from 2003 to 2008. Participants were randomized in a 1:1 ratio 
by the study pharmacist according to the randomization schedule 
prepared by the independent statistician. Participants received 
either JE-CV on day 0 followed by placebo (vaccine diluent) on 
day 28 [Group A] or placebo on day 0 followed by JE-CV on day 
28 [Group B] (Fig. 1). Safety assessments were made and samples 
collected for safety and immunological evaluations before treat-
ment on day 0, and on days 14, 42 and 56. Viremia was assessed 
at 14 days after each immunization. All injections were given as 
0.5 mL subcutaneously. At month 6, all participants returned to 
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as “>ULQ” was converted to “2ULQ”, where “ULQ” was the 
upper limit of quantification. The primary immunogenicity 
outcome was the proportion of participants who seroconverted 
(PRNT
50
 ≥20) to JE-CV 28 days following a single dose of vac-
cine. Secondary immunogenicity outcomes included the propor-
tion of participants who seroconverted to between one and four 
wild-type JEV strains 28 days after vaccination and retained neu-
tralizing antibodies (≥10) to these wild-type JEV strains during 
the long-term follow-up period. Neutralizing GMT for JE-CV 
and wild-type JEV strains was calculated by log transformation 
of the observed titer for each participant and calculation of the 
arithmetic mean. An analysis of the neutralizing GMT and sero-
conversion rates at interim time points and in response to a sec-
ond dose of JE-CV was also undertaken.
Statistical methods. All statistical methods examined a two-
sided, non-directional test of the hypothesis with significance 
set at 5%. The study was not powered to show statistically sig-
nificant treatment differences and the immunogenicity com-
parisons in this study are therefore exploratory. A sample of 100 
participants per group was selected to detect AEs. A sample size of 
200 participants receiving vaccine compared to their indepen-
dent receipt of placebo (separated by one month) established 
an upper bound of 0.015 for the 95% CI for the incidence of 
an AE in the case that the event was not observed. Differences 
in baseline parameters including age, gender, ethnicity and 
pre-existing flavivirus antibodies between treatment groups 
was assessed by ANOVA. Seroconversion rates were analyzed 
using logistical regression methods and the persistence of the 
immune response to wild-type JEV serotypes was assessed 
from months 7 to 24 using McNemar’s test. For neutralizing 
GMTs, the geometric mean ratio after month6 between Group 
C (single-dose group) and Group D (two-dose groups) was 
calculated by ANOVA and was considered significant if the 
95% CI ratio did not contain the value one. A Kaplan-Meier 
survival analysis was used to estimate the proportion of par-
ticipants maintaining seroconversion to JE-CV from month 
6 to 60 with separate analyses undertaken to compare par-
ticipants given a single dose of vaccine and those given two 
doses of vaccine (log rank test). Safety analyses summarized 
the incidence of AEs between treatment groups and were not 
assessed for significance. All participants who received at least 
one injection of vaccine or placebo (202 participants) were 
included in the assessment of safety. The Intent-to-treat (ITT) 
population consisted of those participants who had provided 
day 0 (baseline) and post-immunization (day 56) blood samples 
for antibody analysis (201 participants). The per protocol (PP) 
population included the ITT population who were flavivirus 
naïve by PRNT
50
 and had no major protocol deviations.
Conclusion
The JE-CV vaccine was safe and highly immunogenic in healthy 
volunteers, including those with prior flavivirus exposure. The 
high seroconversion rate and persistence of neutralizing anti-
bodies to the vaccine and wild-type JEV strains up to at least 
human immunodeficiency virus or hepatitis B virus surface anti-
gen in the screening sample; if service women were lactating or 
intended to become pregnant during the course of the trial, if 
personnel had a history of excessive alcohol consumption, drug 
abuse, significant psychiatric illness or a known (or suspected) 
physiological or structural condition that compromised the 
integrity of the blood-brain barrier.
Safety evaluation. The primary safety outcome evaluated 
AE incidence rates up to 28 days post-immunization. Safety 
assessments were based on AE, vital signs (including body tem-
perature), physical examination and routine clinical laboratory 
evaluations. Monitoring for SAEs occurred throughout both the 
initial and long-term follow-up phase of the study. Daily diary 
cards, rulers, thermometers were issued to all participants to aid 
recording of AEs, new medications and oral body temperature. 
Adverse events were observed, reported or elicited by interview 
(aided by the examination of participant diary cards) and coded 
using the Medical Dictionary for Regulatory Activities version 6 
(Maintenance and Support Services Organization, Chantilly, VA 
USA). Severity was deemed mild (aware of sign/symptom but 
easily tolerated, able to perform duties), moderate (discomfort to 
cause interference with duties) or severe (incapacitating, preven-
tion of duties). Local injection site reactions and rash was deemed 
mild (<2 cm or rash restricted to an area equivalent to one limb), 
moderate (≥2 cm or rash equivalent to an area >one limb) or 
severe (≥6 cm or rash equivalent to an area >half the body).
Serological tests. Serum was stored at -70 ± 5°C from samples 
obtained at screening, days 14, 28, 42, 56, months six and seven 
and annually through year five thereafter. For the determination 
of PRNT, test samples were heat inactivated and three ten-fold 
serial dilutions were prepared in duplicate. They were mixed 
with a fixed amount of virus, incubated for one hour at 37°C 
and plated on LLC-MK2 cells in six-well plates. Titers are deter-
mined as described by Russell et al.18 Sera were tested by a single 
technician. All samples from a single time point were tested on 
the same day. A positive control was used throughout the tests to 
ensure consistency of the results. Serum samples collected post-
treatment were tested for neutralizing antibodies to JE-CV virus 
and four wild-type JEV isolates: a genotype I isolate from Korea 
of 1991 (1991 TVP-8236), a genotype II isolate from Thailand 
of 1983 (B1034/8), a genotype III isolate from China of 1949 
(Beijing) and a genotype IV isolate from Indonesia of 1981 (JKT 
9092/TVP-6265). Sera collected prior to immunization was 
tested by PRNT
50
 for evidence (titer ≥10) of previous exposure to 
flaviviruses including Alfuy, dengue virus serotypes 1, 2, 3 and 
4, JEV, Murray Valley encephalitis, yellow fever or to West Nile 
(Kunjin strain) viruses.
Immunogenicity. Seroconversion was defined as a change in 
anti-JE-CV antibody titer of <10 to ≥10 between pre- and post 
immunization samples or a four fold increase from baseline if pre-
existing JEV antibodies existed. A seroprotective antibody titer 
was defined as PRNT
50
 ≥10 to JE-CV according to Hombach, 
2005.9 Any PRNT
50
 value reported as “LOQ” was converted 
to “LOQ/2,” where LOQ was the lower limit of quantifica-
tion, defined as 10 for this study. Any PRNT
50
 value reported 
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60 months after single-dose primary vaccination suggests JE-CV 
may be able to be used in a single dose regimen in persons living 
in non-JEV endemic areas.
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